Cancer is a threat to the human life. This is because it has become of the leading causes of endless deaths and disabilities. Cancer is a collective term for numerous diseases, which differ in severity from one person to another. These differences are influenced by genetics, hormones and other biologically- related factors. The most notorious cancer in women and men is breast cancer and prostate cancer respectively. Recently, Dr. Clay Siegall, an expert in the field of cancer therapy, discussed the advances that have been made in the field and their benefits. It has been known that human genes, which have unique DNA codes and sequence, predispose them to the development of specific diseases like cancer.
Genetic testing, which involves the study of DNA code and sequence in the diagnosis and treatment of diseases like cancer, has helped physicians to make faster and accurate diagnoses. This way, they have been able to develop targeted treatment for individual patients. This process has facilitated the quick diagnosis of prostate cancer, which for many years relied on a slower process of blood work, biopsies, and ultrasounds. Clay said that the success in genome sequencing has enabled a Dutch hospital to develop an innovative method of diagnosing prostate cancer within two weeks. With such prompt diagnosis, patients are able to start immediate treatment.
About Clay Siegall
Dr. Clay Siegall is the co-founder and CEO of Seattle Genetics, a Seattle-based biotech company that focuses on the development of targeted cancer therapies. Clay has relied on extensive research, scientific innovation and drug development practices to build Seattle Genetics from scratch. Today, the company is an authority in the development of antibody-drug conjugates (ADCs). Its first FDA-approved drug is ADCETRIS. They are also developing a pipeline of over 20 drugs. Clay has entered into strategic partnerships with leading pharmaceutical companies.
Clay Siegall was inspired to venture into the field of cancer therapy after watching a close family member suffer from the severe disease. He studied zoology at the University of Maryland. Later he enrolled in George Washington University where he attained a PhD in Genetics. Previously, the successful scientist worked for various pharmaceutical companies, including the National Cancer Institute, Pharmaceutical Research Institute and Bristol-Myers Squibb. He has also held top leadership positions at Ultragenyx Pharmaceutical, Mirna Therapeutics, and Alder Biopharmaceuticals.